Status:
ENROLLING_BY_INVITATION
Community Health Navigator Program to Promote Cancer Screenings Among DDBHH People
Lead Sponsor:
Gallaudet University
Conditions:
Cancer
Deafness
Eligibility:
All Genders
45-80 years
Phase:
NA
Brief Summary
Intervention to promote cancer screenings among deaf, deafblind, and hard of hearing participants who have not received screening within the recommended guideline.
Detailed Description
Study hypothesizes that the intervention that involves utilization of a DDBHH CHN will result in (i) DDBHH patients demonstrating greater adherence to screening compared to DDBHH patients who were ass...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study
- Male or female at birth age 45-80yo or female at birth age 45-80yo; age-eligible according to screening criteria
- Self-reported diagnosis of bilateral hearing loss at birth or prior to 13 years old (defined as "early deafness") and use ASL
- Willingness to adhere to the CHN clinical trial regimen
- Willingness to provide cancer screening verification documentation; this will be reviewed during the informed consent procedure
- Access to necessary resources to support video-based communication
- Non-adherent to one or more cancer screening guidelines for breast, lung, prostate, colon, cervical cancers will be those who reported not having had the appropriate recommended screenings within the past year to cancer screening questions in the HINTS-ASL survey
Exclusion
- Presence of full ability to hear in one or both ears beyond 13 years of age
- Younger or older than the age cutoff for the recommended cancer screening
- Not capable of independently conducting the activities of daily living
- In compliance with age- or risk-specific screening at the time of evaluation for study eligibility
- Are currently undergoing cancer treatment or being evaluated for the presence of cancer at the time of evaluation for study eligibility
- Will be engaged in more than 21 consecutive days of travel during the eleven-month study window
- Knows other participants at baseline
Key Trial Info
Start Date :
September 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06492993
Start Date
September 30 2023
End Date
August 31 2026
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gallaudet University
Washington D.C., District of Columbia, United States, 20002